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ABSTRACT  
Background: Despite successful H. pylori (HP) eradication, some individuals remain at risk 
of developing gastric cancer (GC). Previous studies showed that aspirin was associated with a 
reduced GC risk. However, whether aspirin can reduce GC risk in HP-eradicated subjects 
remains unknown. We aimed to determine the chemopreventive effect of aspirin in HP-
eradicated subjects. 
Methods: We identified subjects who had received a prescription of clarithromycin-based 
triple therapy for HP between 2003 and 2012 from a territory-wide healthcare database. The 
observation period started from commencement of HP therapy (index date), and the follow-
up was censored at the end of the study (December 2015), death or GC diagnosis. Aspirin use 
was defined as ≥once weekly use. Subjects who failed HP eradication or diagnosed with GC 
within 12 months of HP therapy were excluded. The hazard ratio (HR) of GC with aspirin use 
was calculated by Cox model with propensity score adjustment for age, sex, comorbidities 
and concurrent medications.  All statistical tests were two-sided.  
Results: The median follow-up was 7.6 years (IQR: 5.1-10.3 years), and 169 (0.27%) out of 
63,605 patients developed GC. The incidence rate of GC was 3.5 per 10,000 person-years. 
Aspirin use was associated with a reduced GC risk (HR 0.30, 95% CI: 0.15-0.61). The risk of 
GC decreased with increasing frequency, duration and dose of aspirin (all p-trend <0.001). 
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Conclusions: Aspirin use was associated with a frequency-, dose- and duration-dependent 
reduction in GC risk after HP eradication. The effect was most prominent in those who used 
aspirin daily or for ≥ 5 years. 
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INTRODUCTION 
Gastric cancer is the fifth most common cancer and the third leading cause of cancer related 
mortality in the world (1). Helicobacter pylori (H. pylori) infection is a major gastric 
carcinogen, which triggers and promotes the Correa’s gastric carcinogenesis cascade (2). 
Individuals infected with H. pylori have more than 3-fold increase in risk of gastric cancer (3), 
and previous meta-analyses have shown that the risk of gastric cancer development was 
reduced by 33%-47% after H. pylori eradication (4, 5). However, the role of other modifiable 
risk factors, particularly the role of medications on subsequent risk of gastric cancer 
development has not been thoroughly examined.  
Meta-analyses of observational studies suggest that aspirin reduces gastric cancer risk, 
while long-term follow-up of randomized trials of aspirin in preventing cardiovascular events 
shows a statistically non-significant trend favouring reduction in gastric cancer risk (6, 7). 
With low dose aspirin, the chemopreventive effect is unlikely to be mediated solely through 
cyclooxygenase (COX)-2 inhibition. Other non-COX related pathways have been proposed, 
such as phosphatidylinositol 3-kinase (PI3K) (8, 9), nuclear factor (NF)- B (10), Wnt-ß-
catenin, extracellular signal-regulated kinase (ERK) and activated protein1 (AP-1) (11), 
which increases the complexity underlying the chemopreventive effects of low dose aspirin.  
To date, most published studies on the role of aspirin in gastric chemoprevention 
included both H. pylori-infected and H. pylori-negative subjects. Only a few studies with 
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limited sample size performing stratified analysis according to H. pylori statuses which 
showed that the protective effect of aspirin was larger in H. pylori-infected subjects (12-14). 
No study has attempted to determine the role of aspirin in gastric cancer development after H. 
pylori eradication. In addition, the dose- and duration-benefit relationships remain largely 
elusive (15). As aspirin is also associated with an increased risk of gastrointestinal bleeding, 
particularly in H. pylori-infected subjects, the actual beneficial effects of aspirin as 
chemoprevention remains to be determined (16). 
We aimed to determine the role of aspirin in gastric cancer development in a large 
cohort of H. pylori-infected subjects who had received H. pylori eradication therapy.  
 
METHODS 
Data source  
This study used the data from the electronic database of the Clinical Data Analysis and 
Reporting System (CDARS) of the Hong Kong Hospital Authority (17). This electronic 
database system has been previously established for both audit and research purposes (18-22). 
The CDARS used the International Classification of Diseases, Ninth Revision (ICD-9) for 
disease coding. High accuracy of the coding with positive and negative predictive values of 
more than 90% have been demonstrated in previous studies (19, 23). An anonymous patient 
identifier is generated by the system to protect patient confidentiality. Owing to the 
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retrospective nature of this study, written informed consent could not be obtained, and the 
study protocol was approved by the Institutional Review Board of the University of Hong 
Kong and the West Cluster of Hospital Authority, Hong Kong (reference no: UW 16-545).  
 
Study Subjects  
We recruited all H. pylori-infected adult patients aged 18 years or above who had received a 
course of clarithromycin-based triple therapy between 1 January 2003 and 31 December 2012. 
This was identified by the co-prescription of one of the proton pump inhibitors (PPIs) with 
clarithromycin and either amoxicillin or metronidazole with the correct doses, same 
prescription start dates and a treatment duration of 7-14 days (24). Because of the low 
clarithromycin resistance rate (8%) (25) and high eradication rate (> 90%) in Hong Kong (26),  
clarithromycin-based triple therapy remained the first-line anti-H. pylori treatment in this 
study period. H. pylori infection was diagnosed by either histology or urea breath test because 
H. pylori serology and stool antigen tests were unavailable in the public hospitals. 
As the diagnosis of gastric cancer may be delayed, we excluded patients with gastric 
cancer diagnosed within the first year of receiving H. pylori therapy. Patients who had prior 
history of gastric cancer, prior gastrectomy or failed H. pylori eradication were also 
considered ineligible. Failure of H. pylori eradication was identified by the subsequent 
prescriptions of (a) another course of clarithromycin-based triple therapy, (b) a second-line 
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therapy (either PPI-levofloxacin-amoxycillin or bismuth-based qudadruple therapy), or (c) a 
third-line therapy (rifabutin-based therapy). The patient disposition is illustrated in Figure 1, 
and the time frame is depicted in Supplementary Figure 1. 
 
Outcomes 
The primary outcome of this study was the development of gastric adenocarcinoma after H. 
pylori eradication therapy. The observation period started from the date of H. pylori 
eradication therapy (i.e. index date), and patients were censored at gastric cancer diagnosis, 
death, their last clinic visit, or the end of study (31 December 2015) if they had at least one 
follow-up in 2016. Patients diagnosed with gastric adenocarcinoma were identified using the 
ICD-9 (International Classification of Diseases, ninth revisions) (Supplementary Table 1), 
and those diagnosed with gastric lymphoma were excluded. The earliest date of 
hospitalization for the workup or treatment of gastric cancer was used to define the date of 
gastric cancer diagnosis.  
 
Study variables 
The primary exposure of interest was aspirin use after receiving H. pylori eradication therapy. 
Potential confounders included the age of receiving triple therapy, gender, smoking and 
alcohol use, past history of peptic ulcer disease and other comorbidities (diabetes mellitus, 
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dyslipidemia, hypertension, obesity, congestive heart failure, atrial fibrillation, ischemic heart 
disease, chronic renal failure, cirrhosis and stroke) as well as use of other medications (non-
steroidal anti-inflammatory drugs [NSAIDs], cyclooxygenase-2 [COX-2] inhibitors, 
clopidogrel, metformin, statin and PPIs). As smoking and alcohol use were not included in 
the CDARS, we identified smoking- and alcohol-related diseases as in the study by Poulsen 
et al (27). We defined patients who smoked either directly by the ICD-9 code of V15.82 or 
indirectly by the presence of chronic obstructive pulmonary disease (COPD) (ICD-9 codes: 
491, 492, 496). Alcohol use was indicated by alcohol-associated diseases, which included 
gastrointestinal, hepatic, psychiatric and neurological diseases (ICD-9: 291, 303, 305.0, 571, 
980). Supplementary Table 1 shows the diagnostic codes of other variables.  
Previous studies had used various definitions of aspirin use, which was based on 
either the frequency or duration, and were summarized in a recent meta-analysis (7).  For the 
primary analysis in this study, we used the same approach by Thrift et al (28), in which 
exposure of different medications including aspirin was grouped into two categories: non-
regular use (< weekly use; reference group) and regular use (at least weekly use) after 
receiving H. pylori eradication. The total duration of a particular medication use was 
calculated by adding up the treatment duration of each prescription within the observation 
period, starting from the time of eradication. The frequency of this medication use was 
derived by dividing the total treatment duration by the follow-up duration.  We also further 
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classified aspirin use based on other definitions in subsequent analysis in order to (1) ensure 
consistency of the results based on different definitions, and (2) study the dose-response 
relationship of aspirin on gastric cancer risk. In these analyses, the frequency of aspirin use 
was categorized into five groups: (i) never use, (ii) < monthly use, (iii) monthly to <weekly 
use, (iv) weekly to <daily use, and (v) daily use. The duration of aspirin use was categorized 
into four groups: (i) never use, (ii) < 2 years, (iii) 2 -5 years, and (iv) ≥ 5 years (29). The dose 
effect of aspirin was also studied (non-use, < 100 mg and ≥ 100 mg) (7).  
 
Data validation  
Owing to the anonymity of individuals in the CDARS, only the clinical details of patients 
who were followed up in our center (Queen Mary Hospital), which is one of the acute 
hospitals and a tertiary referral center in Hong Kong, could be retrieved for data validation.  
 
Statistical analyses  
All statistical analyses were performed using R version 3.2.3 (R Foundation for Statistical 
Computing, Vienna, Austria) statistical software. Continuous variables were expressed as 
median and interquartile range (IQR). Continuous variables and categorical variables of two 
groups were compared by Mann-Whitney U-test and chi-square test or Fisher’s exact test, 
respectively. Cox proportional hazards model was performed to evaluate the hazard ratio (HR) 
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of gastric cancer development with aspirin use. The Cox proportional-hazard assumption was 
examined by a ‘complementary log-log’-scaled Kaplan-Meier plot, and was regarded to be 
satisfactory. Schoenfeld residuals (with a p-value > 0.05) for each covariate also confirmed 
that the assumption was met.   
In this study, propensity score adjustment was used to control for the confounders (30, 
31). The score represents the probability of assigning aspirin use to an individual that is 
dependent on these covariates (age of receiving H. pylori eradication therapy, sex, smoking, 
alcohol use, comorbidities and concomitant medications). The weighting of each covariate 
was derived from multivariable logistic regression. By adjusting for the measured 
confounding using propensity score, any difference in the outcome (gastric cancer 
development) would be possibly due to the effect of aspirin only. As unmeasured 
confounding could still bias the result, subjects in the extreme ends of the propensity score 
distribution were excluded (32). Twenty categories of 5% each for the propensity score 
distribution were constructed, and the first and 20th propensity score categories were 
subsequently trimmed. The primary analysis of this study was propensity score adjustment 
with trimming, in which propensity score was used as an adjustment variable in the Cox 
model to calculate the HR after extreme propensity score strata were trimmed. In addition, 
univariate and multivariable analyses (with all covariates included into the Cox model) as 
well as propensity score adjustment without trimming were performed as sensitivity analyses. 
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Subgroup analysis of aspirin effect was done by stratifying the location of the tumour (cardia 
and non-cardia regions). 
We also estimated the propensity score adjusted absolute difference in gastric cancer 
risk between aspirin and non-aspirin users. This was calculated by multiplying the adjusted 
HR minus 1 and the crude incidence rate among non-aspirin users (33).  
To determine whether a frequency-, duration- and dose-response relationship existed 
between aspirin use and gastric cancer developmenet, the P-trend was reported. 
All statistical tests were two-sided, and the criterion to define statistical significance 
was a p-value of < 0.05.  
 
RESULTS 
Patient characteristics  
A total of 63,605 eligible subjects were identified, and the median follow-up was 7.6 years 
(IQR:5.1–10.3 years), making a total of 484,680 person-years. The median age of receiving 
clarithromycin-based triple therapy was 54.8 years (IQR:46.0–65.5 years), and 46.6% were 
men. The patient characteristics are shown in Table 1.  
 
Risk of gastric cancer development 
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One hundred and sixty-nine (0.27%) patients developed gastric cancer after H. pylori 
eradication therapy, with an incidence rate of 3.5 per 10,000 person-years. The median age of 
receiving H. pylori eradication therapy was 66.7 years (IQR:56.6–76.5 years), with a median 
lapse of 4.8 years (IQR:2.8–6.9 years) before gastric cancer development (median age 71.4 
years, IQR:61.6–81.8 years). Thirty-four (20.1 %) cancers developed in the cardia, 98 (58.0 
%) in the non-cardia regions, and the sites were unspecified in 37 (21.9%) cases (ICD-9: 
151.9).  
 
Data Validation 
The clinical details of 14  (out of 169; 8.3%) gastric cancer patients who were followed up in 
our center and fulfilled the inclusion and exclusion criteria were reviewed. All patients had 
negative H. pylori status by histological examination.    
 
Association of aspirin use and risk of gastric cancer  
Twenty five (0.3%) out of 9,045 aspirin users developed gastric cancer (3.7 per 10,000 
person-years). The median duration of aspirin use was 4.9 years (IQR:2.8–7.6 years). Aspirin 
use (at least weekly use) was associated with a lower risk of gastric cancer (HR 0.30, 95% 
CI:0.15–0.61) after propensity score adjustment with trimming (Table 2). The propensity 
score adjusted absolute risk difference between aspirin and non-aspirin use was 2.52 fewer 
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gastric cancers (95% CI:1.40–3.06) per 10,000 person-years. On stratifying the tumour site, a 
reduced risk of gastric cancer was only observed for non-cardia (HR 0.28, 95%:CI 0.12 – 
0.64) but not cardia regions (HR 0.36, 95% CI:0.10–1.33). Similar results were observed in 
sensitivity analyses using either multivariable analysis or propensity score adjustment without 
trimming (Table 2). 
 
Frequency, duration, and dose of aspirin use on risk of gastric cancer   
The frequency-, duration-, and dose-response of aspirin use with gastric cancer development 
were also determined. When compared with the reference group (never use), more frequent 
aspirin use showed a statistically significant decreasing trend of gastric cancer risk (p-
trend<0.001) (Table 3). Daily aspirin use was associated with the lowest cancer risk (HR 
0.21, 95% CI:0.05–0.94) when compared to non-use. A longer duration of aspirin use was 
also associated with a lower risk of gastric cancer versus non-use (HR 0.92 [95% CI:0.51–
1.64] for < 2 years of use, HR 0.27 [95% CI:0.09–0.80] for 2 -5 years of use, and HR 0.07 
[95% CI:0.02–0.31] for ≥ 5 years of use; p-trend<0.001). In addition, a lower risk was 
observed with a higher aspirin dose (HR 0.38 [95% CI:0.18–0.79] for dose of < 100 mg, and 
HR 0.15 [95% CI:0.03–0.65] for dose of ≥ 100 mg versus non-use; p-trend<0.001).   
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DISCUSSION 
The risk of gastric cancer remains high even after successful H. pylori eradication, 
particularly among those with pre-existing pre-neoplastic gastric lesions like intestinal 
metaplasia and dysplasia (34, 35). In this territory-wide study of a large cohort of H. pylori-
infected individuals who had received eradication treatment, we found that users of low dose 
aspirin had a 70% reduction in gastric cancer risk when compared to non-users, with a 
statistically significant trend of frequency-, duration-, and dose-dependent effect 
demonstrated.   
The current study has several strengths over previous studies in investigating the 
chemopreventive effects of aspirin on gastric cancer. First, this is the first study that focuses 
on the role of aspirin in H. pylori-eradicated subjects only. The magnitude of risk reduction in 
this study (HR 0.30 [95%CI:0.15–0.61]) was greater than that reported in the meta-analysis 
by Wang et al (pooled odds ratio [OR] 0.78 [95%CI:0.69–0.87]) including studies on both H. 
pylori-infected and H. pylori-negative subjects (6). One intriguing observation about these 
studies was that the risk reduction of gastric cancer by aspirin was greater among H. pylori-
infected subjects. In a previous case-control study, the OR of gastric cancer with aspirin use 
was 0.60 in the whole cohort and 0.39 in H. pylori-infected subjects, while the 
chemopreventive effect was not statistically significant in non-infected patients (13). In a 
Swedish study, the ORs were 0.70 [95%CI:0.6–1.0] in the whole cohort and 0.60 
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[95%CI:0.4 -1.0] in H. pylori-infected subjects, but again not statistically  significant in non-
infected patients (14). In a nationwide retrospective cohort study from Taiwan, the HR of 
gastric cancer with regular NSAID use was also lower among H. pylori-infected (0.52 
[95%CI:0.39–0.68]) than non-infected subjects (0.80 [95%CI:0.70–0.91]) (36). In addition, 
previous studies failed to consider the role of other concurrent medications that may 
modulate the cancer risk such as statin (37), metformin (38) and PPIs (39). Nevertheless, the 
apparently larger chemopreventive effects of aspirin in H. pylori-eradicated subjects in this 
study should be interpreted with caution.  As the HR of the upper limit of 95% CI was 0.61, 
the effect is compatible with a modest effect as reported in previous studies. 
Second, the majority of previous studies are case-control studies, which are more 
prone to selection, information and recall biases (7). The use of population-based healthcare 
database with complete information of diagnoses and drug prescription records could help to 
address these concerns. In addition, our cohort study is the only study that used propensity 
score analysis with trimming of extreme strata to minimize the likelihood of confounding and 
to reduce bias when estimating the treatment effects (40). Notably, aspirin users were older 
and had more comorbidities (including cardiovascular diseases, hypertension, diabetes 
mellitus and chronic renal impairment) at baseline than the non-aspirin users (Table 1). This 
may indicate that any residual confounding from baseline health differences could only bias 
the association towards the null. In fact, aspirin did not appear to have a protective effect on 
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univariate analysis, which is likely due to the negative confounding effect of older age and 
concomitant comorbidities (41). Therefore, the true beneficial effects of aspirin on gastric 
cancer may be underestimated if these negative confounders are not properly adjusted for. 
Third, previous studies used different criteria to define aspirin usage which was based 
on either the frequency or duration of aspirin use. In addition, some studies did not capture 
the information of subsequent aspirin use after baseline assessment, and did not 
comprehensively characterize the effect of aspirin on gastric cancer risk in terms of frequency, 
duration and dose (7). Our study therefore included both the baseline and subsequent use of 
aspirin into the analysis, and computed the magnitude of effects of aspirin by demonstrating 
the frequency- , duration-, and dose-response relationships. 
Several limitations of the present study should be noted. First, data on some known 
risk factors of gastric cancer like family history, diet, physical activity and socioeconomic 
status were not available in the electronic database. Second, identification via coding may 
underestimate the true prevalence of smoking or alcohol use and obesity, as only patients 
with smoking- or alcohol-related diseases or who were morbidly obese would be coded. To 
be more precise, subjects with smoking and alcohol use in this study should be regarded as 
those with smoking- and alcohol-related health problems. Third, failure of triple therapy was 
identified indirectly by the repeated prescription of clarithromycin-based triple therapy or 
prescription of second and third line therapies, which accounted for 13% of this cohort. Also, 
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some patients might choose not to have further courses of H. pylori eradication therapy after 
failure of the clarithromycin-based triple therapy. However, the retreatment figure was 
similar to the reported failure rate of clarithromycin-based triple therapy in our locality with 
relatively low clarithromycin resistance rate during the study period (25). Fourth, information 
on over-the-counter (OTC) aspirin use and drug compliance could not be ascertained. In 
contrast to western countries, the use of over-the-counter (OTC) aspirin was very unpopular 
in Hong Kong to an extent that local pharmaceutical companies have stopped manufacturing 
generic OTC aspirin. As such, only branded OTC aspirin products are available in Hong 
Kong, which are far more expensive than obtaining from hospital pharmacy (£1 for 16 
weeks). Moreover, medications are prescribed and dispensed in the hospital pharmacy 
simultaneously. Fifth, inherent to all observational studies, the possibility of residual 
confounding of our study cannot be excluded. However, the strong effect estimate of aspirin 
on gastric cancer reduction as well as the consistent frequency-, duration- and dose-effects 
makes this association less likely to be completely annulled due to failure to adjust for 
residual confounders (42). Lastly, the number of gastric cancer cases was relatively low 
among aspirin users (n=25). Although stratified analysis did not reveal a statistically 
significant protective effect of aspirin on cardia cancer development, this may be due to the 
relatively small number of cardia cancer cases (n=34). Further studies, particularly from 
western countries where cardia cancers are more prevalent, are warranted.   
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Aspirin has been demonstrated to have potent chemopreventive effect on various 
cancer types, particularly colorectal cancer (11). It is recently recommended by the U.S. 
Preventive Services Task Force to initiate low-dose aspirin for the primary prevention of 
cardiovascular disease and colorectal cancer in adults aged 50 to 59 years who have a more 
than 10% 10-year risk of cardiovascular disease and not at increased risk of bleeding (43).  
However, aspirin is also known to be a major cause of gastrointestinal bleeding, and the risk-
benefit profile of aspirin use on gastric cancer prevention is yet to be defined. The adjusted 
absolute risk difference between aspirin and non-aspirin use may be considered to be modest 
or even low in our study (2.52 fewer gastric cancers per 10,000 person-years). Therefore, 
further studies are needed to characterize the potential risks of bleeding and the benefits of 
gastric cancer prevention by long-term low-dose aspirin use, especially after H. pylori 
eradication.  
In conclusion, long-term aspirin use after H. pylori eradication therapy was associated 
with a statistically significantly lower gastric cancer risk in a frequency-, duration- and dose-
response trend. This effect was most prominent in those who used aspirin daily or for at least 
5 years. The magnitude of risk reduction in this study of H. pylori-eradicated subjects is 
larger than that reported in prior epidemiological studies which recruited both H. pylori-
infected and non-infected subjects. 
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FIGURE LEGEND 
 
Figure 1: Patient recruitment flow diagram 
Abbreviations: GC, gastric cancer 
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Table 1. Baseline characteristics of all subjects (n=63,605) 
 
Characteristic 
All 
(n=63,605) 
Aspirin users 
(n=9,045) 
Non-aspirin users 
(n=54,560) 
Age at triple therapy (years)*  54.8 (46.0 – 65.5) 67.5 (58.4 – 75.9) 52.9 (44.6 – 62.4) 
Male sex (n, %)  29629 (46.5%) 5184 (57.3%) 24445 (44.8%) 
Duration of follow-up (years)*  7.6 (5.1 – 10.3) 7.5 (5.0 – 10.1) 7.4 (5.0 – 10.1) 
Smoking (n, %) †  1647 (2.6%) 549 (6.1%) 1098 (2.0%) 
Alcohol (n, %) ‡ 556 (0.9%) 84 (0.9%) 472 (0.9%) 
History of GU (n, %)  1463 (2.3%) 388 (4.3%) 1075 (2.0%) 
History of DU (n, %)  1913 (3.0%) 251 (2.8%) 1662 (3.0%) 
DM (n, %)  7436 (11.7%) 2897 (32.0%) 4539 (8.3%) 
Hypertension (n, %)  13173 (20.7%) 5021 (55.5%) 8152 (14.9%) 
Dyslipidemia (n, %) 5082 (8.0%) 2606 (28.8%) 2476 (4.5%) 
Obesity 641 (1.0%) 174 (1.9%) 467 (0.9%) 
IHD (n, %)  5756 (9.0%) 4027 (44.5%) 1729 (3.2%) 
AF (n, %)  2439 (3.8%) 1427 (15.8%) 1012 (1.9%) 
CHF (n, %)  2554 (4.0%) 1502 (16.6%) 1052 (1.9%) 
Stroke (n, %)  4005 (6.3%) 2488 (27.5%) 1517 (2.8%) 
CRF (n, %)  1416 (2.2%) 689 (7.6%) 727 (1.3%) 
Cirrhosis (n, %)  1049 (1.6%) 118 (1.3%) 931 (1.7%) 
Statins (n, %)   13247 (20.8%) 6130 (67.8%) 7117 (13.0%) 
Metformin (n, %)   7974 (12.5%) 2599 (28.7%) 5375 (9.9%) 
NSAIDs/COX-2 inhibitors (n, %)   3565 (5.6%) 580 (6.4%) 2985 (5.5%) 
Clopidogrel (n, %)   990 (1.6%) 651 (7.2%) 339 (0.6%) 
PPIs (n, %)   3316 (5.2%) 1380 (15.3%) 1936 (3.5%) 
* Age was expressed as median (years) with interquartile range 
†  Smoking status was ascertained by the ICD-9 code of V15.82 or the presence of chronic obstructive    
pulmonary disease 
‡ Alcohol use was ascertained by alcohol-associated diseases (including gastrointestinal, hepatic,    
psychiatric and neurological diseases) 
Categorical variables were expressed as number (%) 
Drug use was defined as at least weekly use, and expressed as number (%) 
GU, gastric ulcer; DU, duodenal ulcer; DM, diabetes mellitus; IHD, ischemic heart disease; AF, atrial fibrillation; CHF, 
congestive heart failure; CRF, chronic renal failure; NSAIDs, non-steroidal anti-inflammatory drugs; COX-2, 
cyclooxygenase-2; PPIs, proton pump inhibitors 
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Table 2. Association between aspirin use and risk of gastric cancer for the whole cohort and according to 
gastric cancer sites (non-cardia and cardia regions)  
Aspirin frequency 
Univariate analysis Multivariable analysis PS adjustment without trimming PS adjustment with trimming 
HR 95% CI P* HR 95% CI P* HR 95% CI P* HR 95% CI P* 
Whole Cohort†             
Non-user (<weekly 
use) 
1.00 Reference - 1.00 Reference - 1.00 Reference - 1.00 Reference - 
At least weekly  1.06 0.69–1.62 0.79 0.41 0.24–0.69 <0.001 0.36 0.21–0.63 <0.001 0.30 0.15–0.61 <0.001 
Non-cardia GC‡             
Non-user (<weekly 
use) 
1.00 Reference - 1.00 Reference - 1.00 Reference - 1.00 Reference - 
At least weekly  0.94 0.57–1.55 0.81 0.41 0.22–0.75 0.004 0.37 0.19–0.70 0.003 0.28 0.12–0.64 0.003 
Cardia GC§             
Non-user (<weekly 
use) 
1.00 Reference - 1.00 Reference - 1.00 Reference - 1.00 Reference - 
At least weekly 1.58 0.69–3.62 0.28 0.42 0.16–1.15 0.09 0.34 0.12–1.01 0.05 0.36 0.10–1.33 0.13 
*Cox proprtional hazards model was used to calculate the P values, and the test was two-sided.  
HR, hazard ratio; 95% CI, 95% confidence interval; PS, propensity score; GC, gastric cancer 
† For the multivariable analysis: All patients: n=63,605, GC=169; Non-users: n=54,560, GC=144; Aspirin 
users: n=9,045, GC=25. For PS adjustment with trimming: All patients: n=57,243, GC=151; Non-users: 
n=50,777, GC=139; Aspirin users:n=6,466, GC=12. 
‡ For the multivariable analysis: All patients: n=63,571, GC=135; Non-users: n=54,533, GC=117; Aspirin 
users: n=9,038, GC=18. For PS adjustment with trimming: All patients: n=57,214, GC=122; Non-users: 
n=50,756, GC=114; Aspirin users: n=6,458, GC=8. 
§ For the multivariable analysis: All patients:n=63,470, GC=34; Non-users: n=54,443, GC=27; Aspirin users: 
n=9,027, GC=7. For PS adjustment with trimming: All patients:n=57,122, GC=29; Non-users: n=50,671, 
GC=25; Aspirin users: n=6,451, GC=4. 
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Table 3. HRs and 95% CIs for the association between frequency, duration and dose of aspirin 
use and risk of gastric cancer (propensity score adjustment) 
 
Aspirin Use 
No. of 
patients 
(n=57,243) 
No. of GC 
(n=151) HR 95% CI p-value* Ptrend† 
Frequency       
Never user 47,991 129 1.00 Reference - < 0.001 
< Monthly use  2,204 9 0.90 0.44 – 1.84 0.77  
Monthly to < weekly 
use 
582 1 0.35 0.05 – 2.53 0.30  
Weekly to < daily 
use 
5,125 10 0.30 0.14 – 0.63 0.002  
Daily use 1,341 2 0.21 0.05 – 0.94 0.04  
Duration 
Never user 47,991 129 1.00 Reference - < 0.001 
< 2 years 3,900 16 0.92 0.51 – 0.64 0.77  
2 years to < 5 years 2,464 4 0.27 0.09 – 0.80 0.02  
≥ 5 years 2,888 2 0.07 0.02 – 0.31 < 0.001  
Dose 
Non-user ‡ 50,911 139 1.00 Reference - < 0.001 
< 100 mg 4,607 10 0.38 0.18 – 0.79 0.009  
≥ 100 mg 1,725 2 0.15 0.03 – 0.65 0.01  
* Cox proprtional hazards model was used to calculate the P values, and the test was two-sided.    
† Cox proprtional hazards model was used to calculate the P values, and the test was two-sided 
HR, hazard ratio; 95% CI, 95% confidence interval; GC, gastric cancer 
‡Non-user was defined as < weekly use of aspirin 
 
